Belatacept has been introduced as a promising novel immunosuppressant to the field of transplantation, especially for patients suffering from adverse effects of conventional immunosuppression such as nephrotoxicity. Analysis of rejection episodes under costimulation-based regimen in kidney transplants suggested that high percentages of circulating CD4+ CD57+ PD1- cells pre-transplantation may be predictive markers for belatacept-resistant acute rejection (BRR) (1). We investigated this particular subset in one of our face transplant recipients who experienced complications of CNI-based immunosuppression.
Immunological characteristics of a patient with Belatacept-resistant acute rejection after face transplantation. Am J Transplant. 2016 Jul 26. doi: 10.1111/ajt.13977.
Krezdorn N, Murakami N, Pomahac B, Riella LV.
